MedPath

GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
First Posted Date
2005-06-23
Last Posted Date
2017-01-20
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
797
Registration Number
NCT00115492
Locations
🇨🇦

GSK Investigational Site, Trois Rivieres, Quebec, Canada

Dental Pain (Following Third Molar Tooth Extraction) Study

Phase 3
Completed
Conditions
Surgery, Dental
Dental Pain
First Posted Date
2005-06-14
Last Posted Date
2017-01-19
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT00114049
Locations
🇺🇸

GSK Investigational Site, Austin, Texas, United States

COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis

Phase 3
Completed
Conditions
Arthritis, Rheumatoid
First Posted Date
2005-06-08
Last Posted Date
2017-03-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
2208
Registration Number
NCT00113308
Locations
🇬🇧

GSK Investigational Site, Northampton, Northamptonshire, United Kingdom

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Phase 3
Completed
Conditions
Epilepsy, Partial
Epilepsy
First Posted Date
2005-06-07
Last Posted Date
2016-12-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
244
Registration Number
NCT00113165
Locations
🇺🇦

GSK Investigational Site, Lviv, Ukraine

A New Oral Treatment For Type II Diabetes Mellitus

Phase 2
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: DEN 15 mg
Drug: Placebo
Drug: DEN 30 mg
Drug: DEN 2.5 mg
Drug: DEN 7.5 mg
Drug: DEN 45 mg
First Posted Date
2005-05-26
Last Posted Date
2018-03-21
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
375
Registration Number
NCT00111800
Locations
🇸🇪

GSK Investigational Site, Stockholm, Sweden

Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

Phase 2
Completed
Conditions
Neoplasms, Breast
Interventions
First Posted Date
2005-05-26
Last Posted Date
2017-05-31
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
49
Registration Number
NCT00111787
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

Phase 2
Completed
Conditions
Hepatitis C, Chronic
Thrombocytopenia
Hepatitis C
Interventions
Other: Placebo
First Posted Date
2005-05-16
Last Posted Date
2012-06-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
75
Registration Number
NCT00110799
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray

Phase 3
Completed
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
First Posted Date
2005-04-29
Last Posted Date
2016-09-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
56
Registration Number
NCT00109486
Locations
🇩🇰

GSK Investigational Site, Randers, Denmark

A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine

Phase 3
Completed
Conditions
Diphtheria
Acellular Pertussis
Tetanus
First Posted Date
2005-04-27
Last Posted Date
2016-09-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
4116
Registration Number
NCT00109330
Locations
🇺🇸

GSK Investigational Site, Norfolk, Virginia, United States

Perennial Allergic Rhinitis Study In Pediatric Subjects

Phase 3
Completed
Conditions
Rhinitis, Allergic, Perennial
First Posted Date
2005-04-21
Last Posted Date
2017-01-19
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
558
Registration Number
NCT00108914
Locations
🇸🇰

GSK Investigational Site, Nitra, Slovakia

© Copyright 2025. All Rights Reserved by MedPath